Oncology Central

Novel CAR T-cell therapy demonstrates efficacy in non-Hogkin lymphoma trial

Results from the TRANSCEND NHL 001 trial have demonstrated promising results for a novel form of CAR T-cell therapy, termed JCAR017, in patients with poor-prognosis relapsed or refractory non-Hodgkin lymphoma. The findings were presented recently at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium (25–27 January, CA, USA).

JCAR017 is a CD19 directed CAR T-cell product, comprising individually formulated CD4+ and CD8+ suspensions, which are administered in a flat dose.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.